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OBJECTIVE — Observational studies assessing the association of combination therapy of
metformin and sulfonylurea on all-cause and/or cardiovascular mortality in type 2 diabetes have
shown conﬂicting results. We therefore evaluated the effects of combination therapy of sulfo-
nylureas and metformin on the risk of all-cause mortality and cardiovascular disease (CVD)
among people with type 2 diabetes.
RESEARCH DESIGN AND METHODS — A MEDLINE search (January 1966–July
2007) was conducted to identify observational studies that examined the association between
combinationtherapyofsulfonylureasandmetforminonriskofCVDorall-causemortality.From
299relevantreports,9wereincludedinthemeta-analysis.Inthesestudies,combinationtherapy
of metformin and sulfonylurea was assessed, the risk of CVD and/or mortality was reported, and
adjusted relative risk (RR) or equivalent (hazard ratio and odds ratio) and corresponding vari-
ance or equivalent was reported.
RESULTS — The pooled RRs (95% CIs) of outcomes for individuals with type 2 diabetes
prescribed combination therapy of sulfonylureas and metformin were 1.19 (0.88–1.62) for
all-cause mortality, 1.29 (0.73–2.27) for CVD mortality, and 1.43 (1.10–1.85) for a composite
end point of CVD hospitalizations or mortality (fatal or nonfatal events).
CONCLUSIONS — The combination therapy of metformin and sulfonylurea signiﬁcantly
increased the RR of the composite end point of cardiovascular hospitalization or mortality (fatal
and nonfatal events) irrespective of the reference group (diet therapy, metformin monotherapy,
or sulfonylurea monotherapy); however, there were no signiﬁcant effects of this combination
therapy on either CVD mortality or all-cause mortality alone.
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T
ype 2 diabetes is associated with in-
creased risk of all-cause mortality
and cardiovascular disease (CVD).
However, clinical trials to date have not
demonstrated that achieving normal glu-
cose levels can reduce the risk for cardio-
vascular events.
In the UK Prospective Diabetes Study
(UKPDS), intensive blood glucose reduc-
tion was achieved using metformin ther-
apy in diet-treated overweight patients,
resultinginadecreasedriskofmyocardial
infarction and all-cause mortality. How-
ever, when a combination of metformin
and sulfonylurea was prescribed in the
same trial for glycemic control, there was
a signiﬁcant increased risk of diabetes-
related death and all-cause mortality
rather than a beneﬁcial effect, a ﬁnding
attributedbytheinvestigatorstobedueto
chance (1). In the UKPDS, sulfonylureas
themselves were not associated with the
risk of diabetes-related death or myocar-
dial infarction (2), but in previous studies
such as the University Group Diabetes
Program(UGDP)someincreasedriskwas
seen (3), and a warning about increased
risk of CVD is included in the Federal
Drug Administration–approved label for
this class of drugs.
A recent systematic review of clinical
trials of diabetes therapies noted that data
onlong-termoutcomeswerenotavailable
in most clinical trials (4). Observational
studies investigating the association be-
tween combination therapy of metformin
and sulfonylureas and risk of CVD and
mortality have reported conﬂicting re-
sults. Some studies have reported that the
use of this combination therapy increases
the risk of all-cause and CVD mortality
(5), while others have reported no associ-
ation(6,7)oradecreasedriskofmortality
from all causes and CVD (8). Since these
are likely the most commonly prescribed
medications for type 2 diabetes, the pos-
sibleincreaseinriskofall-causemortality
andcardiovasculareventsistroubling(1).
Given these inconsistencies in the liter-
ature and the lack of clinical trials assess-
ing the long-term effects of combination
therapy of sulfonylureas and metformin,
we conducted a meta-analysis of observa-
tional studies to examine the association
betweencombinationtherapyofsulfonyl-
ureasandmetforminandriskofCVDand
all-cause mortality.
RESEARCH DESIGN AND
METHODS
A literature search of the MEDLINE data-
base (from January 1966 through July
2007) was conducted using the medical
subject headings “diabetes mellitus, type
2;” “drug therapy, combination;” “drug
combinations;” “sulfonylurea com-
pounds;” “acetohexamide;” “chlorprop-
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“glyburide;” “glipizide;” “biguanides;”
and “metformin” and keyword
“glimepiride.” The search was restricted
to include studies conducted only in hu-
man subjects. Studies were also identiﬁed
through a search of references cited in the
original published studies and relevant
review articles.
The contents of 299 abstracts or full-
text manuscripts identiﬁed during the lit-
erature search were reviewed inde-
pendently by two investigators in dupli-
cate to determine whether they met the
criteria for inclusion. When there were
discrepancies between investigators for
inclusion or exclusion, a third investiga-
torconductedadditionalevaluationofthe
studyandthediscrepancieswereresolved
in conference. The following inclusion
criteria were used for study selection: 1)
observational study that investigated the
relationship between combination ther-
apy with metformin (biguanides) plus
sulfonylureas and risk of CVD and/or
mortality, 2) adjusted relative risk (RR) or
equivalent (i.e., hazard ratio, odds ratio)
andcorrespondingvarianceorequivalent
reported, and 3) diagnosis of type 2 dia-
betesestablishedusingthestandardcrite-
ria for the time of the study.
All data were independently ab-
stracted in duplicate. Differences in data
extraction were resolved in conference
and by referencing the original publica-
tion. No authors were contacted to re-
quest additional information. A standar-
dizedabstractionformwasusedtorecord
thefollowinginformation:studytitle,ﬁrst
author’s name, year of publication, study
country, study years, name of cohort,
studydesign(prospectiveorretrospective
cohort study or case-control study), du-
ration of follow-up, characteristics of the
study population (sample size, distribu-
tion of age, race, and sex, mean diabetes
duration, mean A1C), type of reference
group, and confounding factors con-
trolledfor.TheRRofcardiovascularmor-
tality/morbidityand/orall-causeorcause-
speciﬁc mortality associated with
combination therapy and their corre-
sponding CIs or SEs were abstracted. The
number of events for all-cause mortality
and cardiovascular mortality/morbidity
were abstracted.
Statistical analysis
RRs were used as the measure of associa-
tion between combination therapy of
metformin and sulfonylurea and CVD
and all-cause mortality. The RRs of each
study were weighted by the inverse of
their variance. To stabilize the variances
and to normalize the distributions, the
RRs and corresponding SEs from each of
the individual studies were transformed
to their natural logarithms. When neces-
sary, SEs were derived from the CIs pro-
vided in each original study.
Theprimarydatafortimetoeventanal-
yses were not available for the combined
cohort. Therefore, for the overall analysis,
RR estimates and 95% CIs for all-cause
mortality and CVD associated with combi-
nation therapy were pooled irrespective of
the reference group used. Subgroup analy-
ses were conducted by reference group
(diet, sulfonylurea monotherapy, or met-
formin monotherapy).
Both ﬁxed-effects and DerSimonian
and Laird random-effects models were
used to calculate the pooled RR of CVD
and all-cause mortality associated with
combination therapy (9). Although both
models yielded similar ﬁndings, results
from the random-effects model are pre-
sented herein owing to signiﬁcant heter-
ogeneity among the studies.
CVD was deﬁned by each of the indi-
vidual studies. We used cardiovascular
mortality and all-cause mortality, as well
as a composite end point of CVD hospi-
talizations (the ﬁrst cardiovascular event
eitherfatalornonfatalevent),ormortality
as our study outcomes. One study re-
ported RRs separately for coronary heart
diseaseandstroke(10).Forthisstudy,we
ﬁrst weighted both of the RRs by the in-
verse of their variance and then pooled
the RRs by using a ﬁxed-effects model to
obtain an overall estimate for the study.
Begg’s rank correlation test was used
to examine the association between effect
estimates and their variances, and Egger’s
linear regression test, which regresses Z
statistics on the reciprocal of the SE for
eachstudy,wasusedtodetectpublication
bias(11,12).Additionally,eachstudywas
omitted one at a time to evaluate the in-
ﬂuence of that study on the pooled esti-
mate. All analyses were performed using
STATA version 8.2 (STATA, College Sta-
tion, TX).
RESULTS— Online appendix Figure
A1 (available at http://dx.doi.org/
10.2337/dc08-0167) depicts the ﬂow of
studies in the meta-analysis. Among 25
studies that met the inclusion criteria, 16
were excluded from the meta-analysis.
Eleven studies did not report CVD or
mortality as an outcome, three studies
were duplicated, and two involved multi-
ple drug combinations. Two studies ex-
amined the association between
combination therapy of metformin and
sulfonylurea in different groups of indi-
viduals according to which drug was
given ﬁrst, and these groups were treated
as separate studies in the meta-analysis.
The characteristics of the study par-
ticipantsandthedesignofthenineobser-
vational studies included in the meta-
analysis are presented in Table 1 (5–
8,10,13–16). Six of the studies were
retrospective cohort studies, two were
prospective cohort studies, and one was a
nested case-control study. Of the nine
studies, one was conducted in the U.S.,
two in Canada, one in Israel, and ﬁve in
European countries. The number of par-
ticipantsinthesestudiesrangedfrom910
in the study by Olsson et al. (10) to
39,721 in the study by Kahler et al. (7).
Mean age ranged from 58.9 to 71.3 years.
Themeanfollow-uptimerangedfrom2.1
to 7.7 years. Among the nine studies,
seven reported all-cause mortality, four
reported cardiovascular mortality, and
threereportedcardiovascularhospitaliza-
tions. Of the 101,733 participants in-
cluded in these studies, 25,091
participants received a combination ther-
apy of metformin and sulfonylurea.
Bruno et al. (13) and Koro et al. (16) did
not specify the number of participants re-
ceiving combination therapy.
Figure 1 depicts the results from the
random-effects models pooling the ad-
justed RRs for all-cause mortality, CVD
mortality, and CVD hospitalizations or
mortality, respectively, associated with
combination therapy of metformin and
sulfonylurea. In addition, it shows the
number of events associated with combi-
nation therapy in comparison with the
control group for all-cause mortality,
CVD mortality, and CVD hospitalizations
or mortality. Pooled RR estimates were
not statistically signiﬁcant for all-cause
mortality or CVD mortality, while the use
of combination therapy was signiﬁcantly
associated with an increased risk of car-
diovascular hospitalizations or mortality.
Insensitivityanalyses,signiﬁcanthet-
erogeneity was present for studies report-
ing all-cause mortality (P  0.001).
However, exclusion of any study did not
change the pooled estimate. For studies
reporting CVD mortality, signiﬁcant het-
erogeneity was present (P  0.001), and
exclusion of the study by Johnson et al.
(15) led to a signiﬁcant increased risk of
CVD mortality associated with combina-
tion therapy of metformin and sulfonyl-
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Signiﬁcantheterogeneitywasalsopresent
for studies that reported cardiovascular
hospitalizations or mortality (P  0.001),
and the exclusion of any study did not
alter the pooled estimate. There was no
evidence of publication bias by rank cor-
relationorregressiontesting(P0.10for
all). In the study by Evans et al. (5), par-
Figure 1—RR estimates and 95% CIs for all-cause mortality (A), CVD mortality (B), and composite end point of CVD hospitalizations or CVD
mortality (C) associated with combination therapy of metformin and sulfonylurea by study and pooled along with proportion of events for each
outcome.
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more than once in computing the pooled
estimate. Analyses were repeated omit-
ting various combinations of this study,
and no substantive changes in results
were noted. Furthermore, we conducted
a sensitivity analysis in which those stud-
ies that did not adjust for duration of di-
abetes or previous CVD were excluded
(6,8,13,14,17). This information is in-
cluded in Table 2.
Subgroup analysis
RR estimates of all-cause mortality, CVD
mortality, and CVD hospitalizations or
mortality associated with combination
therapy of metformin and sulfonylurea
for subgroups deﬁned according to the
comparator treatment are presented in
online appendix Table A1. The estimated
RRswere1.0inallsubgroupsexceptfor
the association between all-cause mortal-
ity and combination therapy compared
with sulfonylurea.
Compared with diet therapy, combi-
nation therapy signiﬁcantly increased the
RR of all-cause mortality, and combina-
tion therapy compared with metformin
monotherapy signiﬁcantly increased the
RR of CVD hospitalizations or mortality.
CONCLUSIONS — In the current
meta-analysis, combination therapy of
metformin and sulfonylurea signiﬁcantly
increased the RR of cardiovascular hospi-
talization or mortality (fatal and nonfatal
events)irrespectiveofthereferencegroup
(diet therapy, metformin monotherapy,
or sulfonylurea monotherapy) used.
However, there were no statistically sig-
niﬁcant effects of combination therapy of
sulfonylurea and metformin on CVD
mortality or all-cause mortality. These re-
sults may help clarify the conﬂicting ﬁnd-
ings of several large observational studies
that examined the effect of combination
therapy with metformin and sulfonyl-
ureas on the risk of CVD events among
patients with type 2 diabetes, while the
association of this combination with all-
cause and cardiovascular mortality re-
mains obscure.
Due to the progressive nature of type
2diabetes,manypatientsareputoncom-
binations of oral antihyperglycemic
agents in order to meet glycemic goals.
For instance, in the recommended algo-
rithm, the combination of sulfonylurea
and metformin is the second step in the
management of patients with type 2 dia-
betes (18). It is likely that patients on
combination therapy are likely to have ei-
ther a more rapidly progressive form of
the disease or a longer duration of diabe-
tes, perhaps both. The reduction of blood
glucose in high-risk obese patients with
type 2 diabetes on metformin therapy
alone in the UKPDS was associated with a
decrease in adverse cardiovascular events
(2). However, when a combination of
metformin and sulfonylurea was pre-
scribed, there was an increased risk,
which is in contrast with some of the ob-
servational studies. This discrepancy may
be due to differences in the population
between these studies.
It may not only be important to re-
duce blood glucose, but also to consider
the choice of agent used to make such a
reduction.Arecentmeta-analysishascre-
ated much controversy about some of the
newer medications used to reduce blood
glucose by suggesting that rosiglitazone
may be associated with an increased risk
of myocardial infarction and possibly
death (19). It is noteworthy that much of
this increased risk with rosiglitazone was
seenincombinationtherapies(20).How-
ever, the interim analysis of the Rosiglita-
zone Evaluated for Cardiac Outcomes
and Regulation of Glycaemia in Diabetes
(RECORD) trial has shown inconclusive
results (21). Our meta-analysis is impor-
tant in the context of that study, as the
combination of metformin and sulfonyl-
urea is the comparator group to the ros-
iglitazone combinations.
Severalobservationalstudieshaveex-
aminedtheassociationbetweencombina-
tion therapy and risk of CVD and all-
cause mortality. Evans et al. (5) carried
out an analysis of a database of 400,000
people in Scotland and identiﬁed 5,730
patients who were prescribed oral hypo-
glycemia agents between 1994 and 2001.
Patients treated with sulfonylureas alone
or in combination with metformin ap-
peared to have an increased RR of adverse
cardiovascular outcomes compared with
those treated with metformin alone. It
was particularly disturbing to note that
the combination of sulfonylurea with
metformin seemed to abrogate the poten-
tial beneﬁt of metformin on CVD out-
come, as seen in the UKPDS (2). A study
by Fisman et al. (14) was carried out
among 2,275 patients with type 2 diabe-
tes and coronary artery disease, as part of
the Bezaﬁbrate Infarction Prevention
Study. The patients were followed for
over 7 years, and the authors demon-
strated that cardiovascular events and
mortality were the same whether gly-
buride, a sulfonylurea, or metformin was
used for treatment. However, there was a
signiﬁcant time-related increased mortal-
ity when the combination therapy was
used.Olssonetal.(10)analyzedmortality
in a small cohort of patients taking sulfo-
nylureas alone or in combination with
metformin and demonstrated a higher
cardiovascular mortality in patients tak-
Table 2—Pooled RR (95% CI) of all-cause mortality, CVD mortality, and composite end point of CVD hospitalizations or CVD mortality
according to different exclusion criteria
All-cause mortality CVD mortality
CVD hospitalizations or CVD
mortality
No. of studies RR (95% CI) No. of studies RR (95% CI) No. of studies RR (95% CI)
All studies 10 1.19 (0.88–1.62) 6 1.29 (0.73–2.27) 7 1.43 (1.10–1.85)
Studies that controlled for important
confounding factors*
6 1.36 (0.93–2.04) 5 1.63 (1.11–2.39) 6 1.55 (1.28–1.87)
Studies that controlled for important
confounding factors†
4 1.34 (0.73–2.47) 3 1.72 (0.93–3.20) 4 1.50 (1.25–1.78)
*Studies that did not control for duration of diabetes excluded. For all-cause mortality, excluding the studies by Gulliford (12), Johnson (14), and Fisman (21). For
CVDmortalityandthecompositeendpointofCVDhospitalizationsorCVDmortality,excludingthestudybyJohnson(23).†Studiesthatdidnotcontrolofduration
ofdiabetesorpreviousCVDexcluded.Forall-causemortality,excludingthestudiesbyGulliford(12),Johnson(14),Olsson(16),Bruno(20),andFisman(21).For
CVD mortality and the composite end point of CVD hospitalizations or CVD mortality, excluding the studies by Olsson (16), Johnson (23), and Bruno (20).
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sulfonylurea alone.
In our meta-analysis, exclusion of the
study by Johnson et al. (15) led to a sig-
niﬁcant increased risk of CVD mortality
associated with combination therapy of
metformin and sulfonylurea. The study
by Johnson et al. (15) reported a reduced
risk of CVD mortality associated with
combination therapy of metformin and
sulfonylurea when compared with sulfo-
nylurea monotherapy, but the study had
many limitations. A large number of pa-
tients were excluded because of short-
term insulin use. Patients prescribed the
combination therapy were 2.3 years
youngerthanthoseprescribedmetformin
monotherapy and 5.8 years younger than
those prescribed sulfonylurea mono-
therapy, a discrepancy that is difﬁcult to
explain.Patientswithmoreseveredisease
or intercurrent illnesses including hospi-
talization for cardiovascular events may
have required insulin use and were there-
fore excluded from the study.
In our analysis, we found a relatively
greater association with fatal and nonfatal
CVD events than in fatal events alone,
suggesting that the incidence of CVD
events may be increased with combina-
tion therapy, but there may have been a
lower case-fatality rate. This contrasts
with the recent data from the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) study (22) in which intensive
treatment with multiple combinations of
diabetestherapieswasassociatedwithde-
creased nonfatal CVD events but in-
creased fatal events. It is impossible to
determinethereasonforthisdiscrepancy,
although it is possible that patients in the
observational studies included in our
analysisdidnothavealevelofglycemiaas
low as that attempted in the ACCORD
trial.
Several hypothetical considerations
may explain the increased risk associated
with such a combination. First, it is pos-
sible that patients needing such a combi-
nation have a more aggressive form of the
disease and therefore more rapid deterio-
ration in glycemic control over time. Sec-
ond, sulfonylureas are associated with
weightgain,whereasmetforminisassoci-
ated with weight loss, as well as some im-
provement in a variety of cardiovascular
risk factors. Any weight gain induced by
the combination may negate some of
these beneﬁcial effects and increase risks.
Other possible explanations include
the known propensity of sulfonylureas to
cause hypoglycemia. When used in com-
bination with a drug like metformin,
which may decrease hepatic glucose pro-
duction, recovery from hypoglycemia
may be impaired. Hypoglycemia may in-
crease the risk of cardiovascular abnor-
malities, including ischemia and a
propensity to cause arrhythmias (23,24).
There is also considerable controversy
abouttheimpactofsulfonylureasonisch-
emicpreconditioning(25),butnothingis
known about the effects of combination
therapy.
Althoughameta-analysisisnotthebest
way to test the efﬁcacy and safety of such a
combination of treatments, it is highly un-
likely that a large-scale clinical trial to test
thishypothesiswillbecarriedout.Thus,we
must rely on data from observational stud-
iestoarriveatconclusionsandmakeappro-
priate recommendations. It is also unclear
to what extent certain biases and method-
ological limitations, such as residual con-
founding, might exist in the studies
included in this meta-analysis, since the
majority of these studies were retrospective
databaseanalyses.Inaddition,thereference
group varied among the studies. For in-
stance, some studies used diet as the refer-
encegroup,whileothersusedsulfonylureas
ormetforminmonotherapyasthereference
group. Finally, we observed substantial
quantitative heterogeneity across the stud-
ies, but the small number of studies limited
ourabilitytoexplorepossiblesourcesofthis
variability. Additionally, ﬁndings from the
subgroup analyses should be interpreted
cautiously, as the number of studies exam-
ined was small.
Overall, our results provide a mix of
reassurance and concern to prescribers of
diabetes medications who use combina-
tion therapies to achieve good glycemic
control. Since sulfonylurea and met-
formin are likely the most widely used
combination, it is possible that such use
leads to early improvement in glycemic
control,which,initself,mayleadtobetter
microvascular outcomes. Although diet
alone is associated with lower mortality
risk, in the UKPDS, diet alone was asso-
ciated with increased microvascular
complications (2). Therefore, one must
balance the risks and beneﬁts of medica-
tions used while making treatment
decisions.
We emphasize that this meta-analysis
has limitations and serves to examine
published data to generate hypotheses.
Such analysis should not be used as a ba-
sisforclinicaldecisions.Wehopethatour
analysis will prompt the planning of fu-
ture clinical trials to determine not only
the value of good glycemic control, but
also the safest and most cost effective way
to achieve glycemic goals. Clearly, we
need further studies to assess the associa-
tionofcombinationtherapyofmetformin
and sulfonylurea with all-cause and/or
cardiovascular mortality as well as to un-
derstand the potential mechanism of its
deleterious effects.
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